Notably, combination therapy using PD‐1/PD‐L1 inhibitors and RT was not associated with a high risk of serious (≥grade 3) immune‐related or radiation pneumonitis, although rates of mild (grade 1–2) pneumonitis were increased in patients who received combination therapy. The gene discussed is CD274; the disease is radiation pneumonitis.